| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
,,,
,,#
* Departments of Immunology,
Medical Biophysics, and
Medicine, University of Toronto, Toronto, Ontario, Canada;
Ontario Cancer Institute/Princess Margaret Hospital, Toronto, Ontario, Canada;
¶ Babraham Institute, Babraham, Cambridge, United Kingdom;
|| Laboratory of Cellular and Molecular Biology National Institute on Aging, National Institutes of Health, Baltimore, MD 00000; and
# St. Michael’s Hospital, Toronto, Ontario, Canada
In concert with the TCR, CD28 promotes T cell survival by regulating the expression of the antiapoptotic protein Bcl-xL. The mechanism by which CD28 mediates the induction of Bcl-xL remains unknown. We show that although signaling through the TCR is sufficient to stimulate transcription of Bcl-xL mRNA, CD28, by activating PI3K and mammalian target of rapamycin, provides a critical signal that regulates the translation of Bcl-xL transcripts. We observe that CD28 induced 4E-binding protein-1 phosphorylation, an inhibitor of the translational machinery, and that CD28 costimulation directly augmented the translation of a Bcl-xL 5'-untranslated region reporter construct. Lastly, costimulation by CD28 shifted the distribution of Bcl-xL mRNA transcripts from the pretranslation complex to the translationally active polyribosomes. These results demonstrate that CD28 relieves the translational inhibition of Bcl-xL in a PI3K/mammalian target of rapamycin-dependent manner.
Related articles in The JI:
This article has been cited by other articles:
|
|
 |
|
  J. Zhang, G. Tsaprailis, and G. T. Bowden Nucleolin Stabilizes Bcl-XL Messenger RNA in Response to UVA Irradiation Cancer Res., February 15, 2008; 68(4): 1046 - 1054. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Boller, A. Schramm, K. T. Doepfner, T. Shalaby, A. O. von Bueren, A. Eggert, M. A. Grotzer, and A. Arcaro Targeting the Phosphoinositide 3-Kinase Isoform p110{delta} Impairs Growth and Survival in Neuroblastoma Cells Clin. Cancer Res., February 15, 2008; 14(4): 1172 - 1181. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Mariotti, J. Foley, U. Jung, T. Borenstein, N. Kantardzic, S. Han, J. T. Hanson, E. Wong, N. Buxhoeveden, J. B. Trepel, et al. Ex Vivo Rapamycin Generates Apoptosis-Resistant Donor Th2 Cells That Persist In Vivo and Prevent Hemopoietic Stem Cell Graft Rejection J. Immunol., January 1, 2008; 180(1): 89 - 105. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.-C. Su, Y.-P. Lin, Y.-J. Cheng, J.-Y. Huang, W.-J. Chuang, Y.-S. Shan, and B.-C. Yang Phosphatidylinositol 3-Kinase/Akt Activation by Integrin-Tumor Matrix Interaction Suppresses Fas-Mediated Apoptosis in T Cells J. Immunol., October 1, 2007; 179(7): 4589 - 4597. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Kowolik, M. S. Topp, S. Gonzalez, T. Pfeiffer, S. Olivares, N. Gonzalez, D. D. Smith, S. J. Forman, M. C. Jensen, and L. J.N. Cooper CD28 Costimulation Provided through a CD19-Specific Chimeric Antigen Receptor Enhances In vivo Persistence and Antitumor Efficacy of Adoptively Transferred T Cells. Cancer Res., November 15, 2006; 66(22): 10995 - 11004. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Colombetti, V. Basso, D. L. Mueller, and A. Mondino Prolonged TCR/CD28 Engagement Drives IL-2-Independent T Cell Clonal Expansion through Signaling Mediated by the Mammalian Target of Rapamycin. J. Immunol., March 1, 2006; 176(5): 2730 - 2738. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Abdelmegeed, N. J. Carruthers, K. J. Woodcroft, S. K. Kim, and R. F. Novak Acetoacetate Induces CYP2E1 Protein and Suppresses CYP2E1 mRNA in Primary Cultured Rat Hepatocytes J. Pharmacol. Exp. Ther., October 1, 2005; 315(1): 203 - 213. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
